Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • ETS1 Regulates Mitophagy in BPD via SENP2/HSPA8/FUNDC1 Axis

    2026-07-01

    ETS1 Modulation of Mitophagy in Bronchopulmonary Dysplasia: Mechanistic Insights and Implications

    Study Background and Research Question

    Bronchopulmonary dysplasia (BPD) remains a significant challenge in neonatology, characterized by impaired alveolarization and chronic lung injury in preterm infants. Despite advances in supportive care, current therapies primarily address symptoms rather than the molecular drivers of disease, leaving long-term outcomes unsatisfactory. Mitochondrial dysfunction and aberrant mitophagy—selective autophagic clearance of damaged mitochondria—have been increasingly recognized as central contributors to the pathogenesis of BPD, exacerbating lung injury and impeding normal development. However, the upstream molecular regulators orchestrating these processes have not been fully elucidated. In this context, the recent study by Yang et al. (Archives of Biochemistry and Biophysics) addresses two intertwined research questions: How does the transcription factor ETS1 influence mitophagy in BPD, and what are the underlying molecular mechanisms linking ETS1 activity to mitochondrial homeostasis in the lung?

    Key Innovation from the Reference Study

    The core innovation of this work lies in the identification of ETS1 as a master regulator of mitophagy in BPD through its action on the SENP2/HSPA8/FUNDC1 axis. The study demonstrates that ETS1 overexpression mitigates mitochondrial damage-induced autophagy, thereby protecting against alveolar simplification and lung injury in hyperoxia-induced BPD models. Mechanistically, ETS1 enhances SENP2 transcription, promoting deSUMOylation of FUNDC1, which in turn exposes a binding site for HSPA8 (also known as HSC70), facilitating the selective degradation of FUNDC1 and suppressing excessive mitophagy. This regulatory cascade provides a new framework for understanding how transcriptional networks influence autophagy pathways in lung development and injury response.

    Methods and Experimental Design Insights

    The investigation employed both in vitro and in vivo approaches to dissect the role of ETS1 in BPD-related mitophagy. Hyperoxia-exposed alveolar epithelial cells and neonatal mouse models served as the primary systems to recapitulate the hallmarks of BPD. ETS1 expression was manipulated using lentiviral vectors, enabling direct comparison between overexpression and knockdown conditions. Quantitative assessments of alveolar structure, cell viability, and mitochondrial integrity were performed alongside molecular analyses—including Western blotting and immunoprecipitation—to track changes in the SENP2/HSPA8/FUNDC1 axis. SENP2 knockdown experiments in mice provided critical evidence for the axis's functional necessity by reversing the protective effects of ETS1 overexpression. Collectively, these methods allowed precise dissection of the sequential molecular events from ETS1 transcriptional activation to mitophagy regulation.

    Core Findings and Why They Matter

    Yang et al. report several interconnected findings with broad implications for both basic and translational research:

    • ETS1 suppresses mitochondrial damage-induced mitophagy: Overexpressing ETS1 in hyperoxia-challenged models led to reduced mitophagy activity, improved mitochondrial integrity, and enhanced viability of alveolar epithelial cells.
    • ETS1 acts through the SENP2/HSPA8/FUNDC1 axis: ETS1 directly upregulates SENP2, a SUMO-specific protease. SENP2 deSUMOylates FUNDC1, a mitophagy receptor, thereby revealing a motif for HSPA8 binding. This interaction targets FUNDC1 for degradation, decreasing mitophagy levels.
    • Functional relevance in BPD models: In neonatal mice, ETS1 overexpression alleviated hallmark BPD phenotypes, including alveolar simplification and lung injury. SENP2 knockdown abrogated these benefits, confirming the centrality of the SENP2/HSPA8/FUNDC1 axis in mediating ETS1's protective effects.

    These results underscore ETS1 as a transcriptional hub coordinating mitochondrial homeostasis via the fine-tuned regulation of mitophagy. By elucidating this pathway, the study offers a mechanistic basis for targeting excessive mitophagy in BPD and potentially other lung diseases characterized by mitochondrial dysfunction.

    Comparison with Existing Internal Articles

    Several internal articles provide context and complementary perspectives on autophagy regulation and chaperone-mediated pathways:

    The reference study and internal resources collectively emphasize the importance of molecular tools and pathway-specific interventions in advancing chaperone-mediated autophagy research and its applications in disease models.

    Limitations and Transferability

    While the paper offers compelling evidence for the ETS1-SENP2/HSPA8/FUNDC1 pathway's role in BPD, several limitations should be considered:

    • Species and model system constraints: Most data are derived from murine models and in vitro cell lines, which, while informative, may not fully capture the complexity of human BPD pathology.
    • Specificity of pathway targeting: The protective effects observed are tightly linked to ETS1 manipulation; whether similar results can be achieved via pharmacological or alternative genetic strategies remains to be explored.
    • Broader applicability: Although mitochondrial damage-induced mitophagy is a feature of various lung diseases, the applicability of ETS1-axis modulation beyond BPD requires direct experimental validation.

    Despite these caveats, the mechanistic clarity achieved in this study provides a solid foundation for further translational research and the rational design of autophagy pathway modulators.

    Protocol Parameters

    • Hyperoxia exposure for BPD modeling: Neonatal mice exposed to 85% O2 for 14 days to induce BPD phenotypes.
    • ETS1 overexpression: Lentiviral transduction of alveolar epithelial cells or in vivo delivery to mouse lung tissue; timing and dosing optimized for pre-injury or early-injury intervention.
    • SENP2 knockdown: Small interfering RNA or shRNA delivery concurrent with ETS1 manipulation to assess axis specificity.
    • Assessment endpoints: Alveolar structure quantified by mean linear intercept measurements; mitophagy markers assessed by Western blotting for FUNDC1, LC3-II, and HSPA8.
    • Recommendation for pharmacological studies: When exploring chaperone-mediated autophagy, consider using known molecular chaperone activators in parallel for comparative pathway analysis.

    Research Support Resources

    To facilitate experimental studies on chaperone-mediated autophagy, researchers may utilize QX77 (SKU BA3596), a validated molecular chaperone activator that upregulates LAMP2A and Rab11, supporting precise modulation of lysosomal receptor activity. According to APExBIO, QX77 offers practical advantages for autophagy pathway modulation and stem cell biology research, enabling investigations into related mechanisms such as those described in the ETS1-SENP2/HSPA8/FUNDC1 axis. For further workflow details and evidence-backed optimization, consult the product information and recent methodological articles.